Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Pfizer, inc. crawled time : 05:00 save search
Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate
Published: 2023-09-07 (Crawled : 05:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.29%
H: 0.49%
C: -0.55%
candidate disease report vaccine positive valneva results phase 2
Pfizer, Teva Pharmaceuticals, Silverstein Properties and Azrieli Group Honored by the America-Israel Friendship League at its Annual Gala
Published: 2022-11-02 (Crawled : 05:00) - prnewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.5%
H: 0.84%
C: -1.47%
teva group
CStone and Pfizer announce NMPA approval of sugemalimab in patients with unresectable stage III non-small cell lung cancer
Published: 2022-06-06 (Crawled : 05:00) - prnewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 1.12%
H: 0.99%
C: 0.13%
approval cancer
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis
Published: 2022-04-12 (Crawled : 05:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -1.17%
H: 1.18%
C: -0.36%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: -22.06%
H: 9.34%
C: -3.89%
myfembree management drug application
Arena Pharmaceuticals INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arena Pharmaceuticals, Inc. - ARNA
Published: 2022-01-05 (Crawled : 05:00) - prnewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.73%
H: 0.0%
C: 0.0%
als
Arena Pharmaceuticals INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arena Pharmaceuticals, Inc. - ARNA
Published: 2021-12-15 (Crawled : 05:00) - prnewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 2.56%
H: 5.0%
C: 4.79%
als
Valneva and Pfizer Complete Recruitment for Phase 2 Trial of Lyme Disease Vaccine Candidate
Published: 2021-07-19 (Crawled : 05:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.17%
H: 0.7%
C: 0.2%
disease phase 2 vaccine trial
U.S. FDA Approves PREVNAR 20™, Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older
Published: 2021-06-09 (Crawled : 05:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.39%
H: 2.15%
C: 2.08%
fda vaccine fda approval order pneumococcal
Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19
Published: 2020-12-12 (Crawled : 05:00) - globenewswire.com
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
| Email alert
Add to watchlist
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
| Email alert
Add to watchlist
covid vaccine authorized covid-19
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.